IMVAX
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs. Its product, IGV-001, is an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the patient’s immune system as a defense mechanism. The company was incorporated in 2015 by David W. Andrews, Craig Hooper, Arthur W. Howe, and Peter B. Corr in Philadelphia, Pennsylvania.
IMVAX
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.imvax.com
Total Employee:
11+
Status:
Active
Contact:
215-485-0071
Email Addresses:
[email protected]
Total Funding:
166.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Actinobac Biomed
Actinobac Biomed focuses on the development of pharmaceutical technologies derived from agents that target LFA-1.
Alvine Pharmaceuticals
Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Bio-Detection K9
Bio-Detection K9 is a biotech company specialized in the canine detection of bacteria and viruses particular of covid-19.
Biofourmis
Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics.
Clear Vascular
Clear Vascular offers Tin-Annexin, an injectable radiopharmaceutical agent for imaging and therapy of inflammatory tissues.
Clinials
Clinials is a participant recruitment platform Using AI to Help Researchers Communicate Medical Information to Patients
Edgemont Pharmaceuticals
Edgemont Pharmaceuticals focuses on the field of neuroscience and develops novel drug formulations and therapies to improve patient care.
Hawkeye Bio
Hawkeye Bio is a medical technology company focused on the early detection of cancer, infectious disease and autoimmune disease.
Immunowake
Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies.
ImpactRx
ImpactRx operates as a promotion research organization for the pharmaceutical industry in the United States.
Inmagene Biopharmaceuticals
It is a leading biotech company focused on immunology-related therapeutic areas.
InSite Vision
InSite Vision develops therapeutic products for common eye problems: infection, pain and inflammation in ocular surgery and glaucoma.
LipUm
LipUm operates as a biotechnology company that offers anti-inflammatory drugs.
Oragenics
Oragenics develops oral probiotic products and antibiotics for humans and companion pets.
Peptinnovate
Peptinnovate Limited, is a U.K. drug development company developing a ‘first in class’ immune regulating therapy for inflammatory diseases.
PNP Therapeutics
PNP Therapeutics is engaged in the development of technology and proprietary products for the treatment of cancer.
PPD
PPD is a global contract research organization that offers drug development, laboratory, and lifecycle management services.
SolAeroMed
SolAeroMed is a developer of a novel therapeutic used to treat obstructive lung diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
HP WILD HOLDING AG
HP WILD HOLDING AG investment in Series C - Imvax
Magnetar Capital
Magnetar Capital investment in Series C - Imvax
Invus
Invus investment in Series C - Imvax
Ziff Capital Partners
Ziff Capital Partners investment in Series C - Imvax
TLP Investment Partners
TLP Investment Partners investment in Series C - Imvax
WILD Group Management
WILD Group Management investment in Series B - Imvax
Magnetar Capital
Magnetar Capital investment in Series B - Imvax
Ziff Capital Partners
Ziff Capital Partners investment in Series B - Imvax
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-16 | Imvax Appoints John M. Limongelli as Chief Legal Officer |
Official Site Inspections
http://www.imvax.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.54 K
- Host name: 141.222.135.34.bc.googleusercontent.com
- IP address: 34.135.222.141
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Imvax"
Imvax - Crunchbase Company Profile & Funding
Organization. Imvax . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Imvax is a biotechnology company focused on the development of novel patient-specific …See details»
Imvax, Inc. - LinkedIn
Imvax, Inc. Biotechnology Research Philadelphia, Pennsylvania 3,165 followers Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived …See details»
Imvax Company Profile 2024: Valuation, Funding & Investors
What is the size of Imvax? Imvax has 49 total employees. What industry is Imvax in? Imvax’s primary industry is Drug Discovery. Is Imvax a private or public company? Imvax is a Private …See details»
Imvax Company Profile: Overview and Full News Analysis
Imvax is dedicated to developing a diverse range of personalized immunotherapies to target solid tumors effectively. In recent news, Imvax presented new data at the 2023 SNO Annual …See details»
Imvax, Inc. Company Profile | Philadelphia, PA | Competitors ...
Find company research, competitor information, contact details & financial data for Imvax, Inc. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Leading Through Transition - PharmExec
Oct 12, 2021 Furey says Imvax has “a problem of privilege” in that it’s realizing many positive early preclinical signals and hopes to be able to develop an organization that can execute on …See details»
Fierce Biotech names Imvax Inc. as one of its "Fierce 15" Biotech ...
Sep 28, 2020 "It is an honor to be named to the 2020 Fierce 15 list, especially among this class of promising biotech companies," said John Furey, Imvax Chief Executive Officer. "2020 has …See details»
Imvax Provides Corporate Update - PharmiWeb.com
Sep 6, 2023 – Seasoned finance executive Stephen Webster appointed to Imvax Board of Directors – PHILADELPHIA--(BUSINESS WIRE)-- Imvax, Inc. , a clinical-stage biotechnology …See details»
Irish-led Imvax raises $112m for brain cancer therapy trials
Jul 20, 2020 Imvax, a US-based clinical-stage biotechnology company led by Irishman John Furey, has raised $112 million (€97.7m) to advance brain cancer cell therapy. Mr Furey joined …See details»
Imvax Announces Publication in Journal for ImmunoTherapy of …
Aug 8, 2023 Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes …See details»
Imvax Inc. Raises $112 Million in Series C Financing - PR Newswire
Jul 16, 2020 Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research …See details»
Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 …
PHILADELPHIA, November 11, 2024--Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas. PHILADELPHIA, …See details»
Imvax Appoints Sean Hemingway as Chief Operating Officer - PR …
Apr 8, 2021 He will also oversee the manufacturing and supply organization, while simultaneously building out Imvax's cell therapy platform. Continue Reading Sean …See details»
Imvax Advances a New Approach to Personalized Cancer …
Imvax is a clinical-stage biotechnology company headquartered in Philadelphia, PA, with a unique platform technology, Goldspire™. Goldspire harnesses decades of research and multiple …See details»
Imvax: Personalized Immunotherapy for Glioblastoma Patients
Imvax is a pioneering clinical biotechnology company developing personalized cancer treatments specifically designed for glioblastoma (GBM) patients. Skip to content GBM Awareness Day is …See details»
Henry Ford Health Doses First Patient in Combination …
DETROIT (July 12, 2023) – Physicians in the Hermelin Brain Tumor Center at Henry Ford Health recently administered the first dose of IGV-001, a combination immunotherapy developed by …See details»
Imvax reports positive results from trial of GBM vaccine IGV-001
Imvax has reported positive results from an ongoing Phase Ib clinical trial evaluating the safety and efficacy of IGV-001 to treat newly diagnosed glioblastoma multiforme (GBM). IGV-001 is a …See details»
Imvax to present at UBS Global Healthcare Virtual Conference - PR …
May 11, 2021 /PRNewswire/ -- Imvax, a clinical stage immuno-oncology company driven to transform patient treatment and outcomes with its novel technology platform,...See details»
Phase 2b of a Promising Brain Tumor Clinical Trial Begins
Aug 9, 2023 Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. ... Jefferson holds itself accountable, …See details»
Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001 …
Jan 26, 2021 Imvax ™ is an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM) and other solid tumors with significant unmet …See details»